Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 207

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Effective elimination of dabigatran by haemodialysis: A phase I single-centre study in patients with end-stage renal disease

Formella, Stephan, Wiegert, Erol, Moschetti, Viktoria, Slowinski, Torsten, Neumayer, Hans-H., Liesenfeld, Karl-Heinz, Lehr, Thorsten, Härtter, Sebastian, Friedman, Jeffrey, Khadzhynov, Dmytro, Wagner, Frank, Peters, Harm, Clemens, Andreas · 2013 · Thrombosis and Haemostasis

Abstract

Summary: Dabigatran, a specific, reversible direct thrombin inhibitor, is used to prevent ischaemic and haemorrhagic strokes in patients with atrial fibrillation. As with every anticoagulant, there is a need to rapidly reverse its effects in emergency situations. In an open-label, single-centre phase I study with two fixed multiple dosing periods, we investigated the pharmacokinetics, pharmacodynamics and safety of dabigatran before, during and after 4 hour haemodialysis sessions with either 200 or 400 ml/min targeted blood flow in seven end-stage renal disease patients without atrial fibrillation. Dabigatran was administered over three days in a regimen designed to achieve peak plasma concentrations comparable to those observed in atrial fibrillation patients receiving 150 mg b.i.d. and to attain adequate distribution of dabigatran in the central and peripheral compartments. Plasma concentration-time profiles were similar in both periods on Day 3 (Cmax: 176 and 159 ng/ml). Four hours of haemodialysis removed 48.8% and 59.3% of total dabigatran from the central compartment with 200 and 400 ml/minute targeted blood flow, respectively. The anticoagulant activity of dabigatran was linearly related to its plasma levels. There was a minor redistribution of dabigatran (<16%) after the end of the haemodialysis session. In conclusion, a 4 hour haemodialysis session can rapidly eliminate a substantial amount of dabigatran from the central compartment with a concomitant marked reduction in its anticoagulant activity. There was a clinically negligible redistribution of dabigatran after haemodialysis. These results demonstrate that haemodialysis can be a suitable approach to eliminate dabigatran in emergency situations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1160/th12-08-0573

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 207

Metadata

Authors
Formella, S., Wiegert, E., Moschetti, V., Slowinski, T., Neumayer, H.-H., Liesenfeld, K.-H., Lehr, T., Härtter, S., Friedman, J., Khadzhynov, D., Wagner, F., Peters, H., & Clemens, A.
Venue
Thrombosis and Haemostasis
Published
2013
Volume
109
Issue
04
Pages
596-605
ISSN
  • 0340-6245 (ISSN-L)
  • 2567-689X
OpenAlex
W2142970733
Cited by
207
References
2
FWCI
26.48
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effective elimination of dabigatran by haemodialysis: A phase I single-centre study in patients with end-stage renal disease. https://app.cochat.ai/papers/10.1160/th12-08-0573
The paper
Formella, S., Wiegert, E., Moschetti, V., Slowinski, T., Neumayer, H.-H., Liesenfeld, K.-H., Lehr, T., Härtter, S., Friedman, J., Khadzhynov, D., Wagner, F., Peters, H., & Clemens, A. (2013). Effective elimination of dabigatran by haemodialysis: A phase I single-centre study in patients with end-stage renal disease. Thrombosis and Haemostasis. https://doi.org/10.1160/th12-08-0573

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.